Using Acalabrutinib in CLL Patients With Ibrutinib Intolerance
Jacqueline C. Barrientos, MD, MS, discusses the role of acalabrutinib, a second-generation BTK inhibitor, that is available for patients with chronic lymphocytic leukemia, but not yet approved.
Jacqueline C. Barrientos, MD, MS, associate professor in the department of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, discusses the role of acalabrutinib (Calquence), a second-generation BTK inhibitor, that is available for patients with chronic lymphocytic leukemia (CLL), but not yet approved by the FDA.
Acalabrutinib has demonstrated activity in patients with CLL who are intolerant to ibrutinib (Imbruvica), says Barrientos. In addition, this agent appears promising in the frontline and for treatment of patients with relapsed/refractory disease.
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
